Smith BB, et al. - Researchers determined the risk of major adverse cardiac events (MACEs) related to noncardiac surgery (NCS) after percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in 282 patients (74.8% male). They found 5.3% incidence of MACE in patients with second-generation DES undergoing NCS. Also, they noted that the incidence of MACE was highest in the first 180 days after implantation of DES. The estimated rate of excessive surgical bleeding was 6.7%; patients who were receiving dual antiplatelet therapy exhibited the highest rate of excessive surgical bleeding. Based on the presence or absence of antiplatelet therapy, however, no significant differences were identified.